Meningococcal B: WA Families & Vaccine Costs | RACGP

Growing concern over cases of Meningococcal B disease in Western Australia is prompting calls for the state government to expand its free vaccination program. Currently, the ACWY vaccine is freely available to children, while the MenB vaccine is only offered to specific at-risk groups, including Aboriginal and Torres Strait Islander children. Advocates are now pushing for universal access to the MenB vaccine, citing the potentially devastating consequences of this particular strain of the disease.

The urgency stems from recent, harrowing experiences like that of five-year-old Charlie Ware, who nearly died after contracting Meningococcal B earlier this year. His mother, Alyce Ware, shared her story, describing how Charlie rapidly became ill and required intensive care, including being placed in a medically induced coma at Perth Children’s Hospital. Ms. Ware emphasizes the importance of preventing other families from enduring a similar ordeal.

Meningococcal disease is caused by bacteria, Neisseria meningitidis, and can lead to severe illness, including meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (blood poisoning). Notice several serogroups of this bacteria, with A, B, C, W, and Y being the most common. The disease can progress rapidly, making early diagnosis and treatment crucial.

Currently, several types of meningococcal vaccines are available. The Centers for Disease Control and Prevention (CDC) identifies six vaccines authorized for use in the United States as of July 1, 2025. These vaccines are designed to protect against one or multiple serogroups. MenACWY vaccines protect against serogroups A, C, W, and Y. MenB vaccines specifically target serogroup B. More recently, MenABCWY vaccines have become available, offering protection against all five serogroups (A, B, C, W, and Y). The CDC notes that protection from these vaccines decreases over time, and consultation with a healthcare provider is recommended to determine appropriate vaccination schedules.

The Royal Australian College of General Practitioners (RACGP) has voiced its support for expanding the free MenB vaccination program in Western Australia. This call comes as families and advocacy groups highlight the financial burden of the MenB vaccine, which is not universally funded. The RACGP’s stance underscores the importance of equitable access to preventative healthcare measures.

The rash associated with meningococcal disease is a key symptom to watch for. A rash that doesn’t fade when pressure is applied – using the “glass test” – can be a sign of the infection. However, it’s important to note that the rash doesn’t always appear, and early symptoms can be similar to those of other illnesses, such as the flu. These symptoms can include fever, headache, stiff neck, nausea, vomiting, sensitivity to light, and confusion.

The availability of different vaccine types allows for tailored vaccination strategies. For example, the CDC outlines varying dosage recommendations for the MenB vaccine depending on risk factors. Individuals aged 16-23 who are not considered at increased risk require two doses, while those aged 10 or older with increased risk require three doses. The MenABCWY vaccines offer a convenient option for individuals needing protection against multiple serogroups in a single visit.

While meningococcal vaccines are highly effective, they don’t guarantee complete protection. The CDC emphasizes that vaccines work well but cannot prevent all cases of the disease. Clinical trials have demonstrated that the vaccines elicit an immune response, suggesting protection, but further data are needed to fully understand their long-term effectiveness. The relative rarity of meningococcal disease makes it challenging to measure vaccine effectiveness definitively, requiring large-scale vaccination efforts to gather sufficient data.

The situation in Western Australia reflects a broader public health debate about the cost-effectiveness of vaccination programs and the balance between individual responsibility and collective protection. Expanding access to the MenB vaccine would likely reduce the incidence of this potentially life-threatening disease, but it would also require a significant investment of public funds. The RACGP’s call for action highlights the need for policymakers to carefully consider these factors and prioritize the health and well-being of the community.

For parents and caregivers, staying informed about meningococcal disease and vaccination options is crucial. Consulting with a healthcare provider is the best way to determine the appropriate vaccination schedule and address any concerns. Early recognition of symptoms and prompt medical attention can significantly improve outcomes for individuals affected by this serious infection.